DCR-PHXC
Phase 3Small molecule
DCR-PHXC is one of 51 small molecule programs targeting Efficacy. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Insulin 320
Novo NordiskPhase 3
DCR-PHXC
DDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
Levocept
SSebela Women's Health Inc.
Phase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary Hyperoxaluria1 trial
Primary Hyperoxaluria Type 11 trial
Primary Hyperoxaluria Type 1 (PH1)1 trial
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria
Active, not recruiting·DDicerna Pharmaceuticals, Inc., a Novo Nordisk company·Phase 3·NCT04042402·75 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCR-PHXC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details